GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
143.23
-0.09 (-0.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close143.32
Open145.63
Bid0.00 x 1000
Ask0.00 x 1200
Day's Range143.05 - 146.79
52 Week Range101.07 - 179.65
Volume438,573
Avg. Volume505,167
Market Cap4.633B
Beta (3Y Monthly)2.89
PE Ratio (TTM)N/A
EPS (TTM)-8.74
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est178.33
Trade prices are not sourced from all markets
  • 5 Marijuana Stocks to Watch
    InvestorPlace11 hours ago

    5 Marijuana Stocks to Watch

    To be honest, I’m not entirely thrilled about investing in marijuana stocks at the moment. Initial products such as Epidiolex and Sativex are used to treat epilepsy and spasticity caused by multiple sclerosis.

  • ACCESSWIRE16 hours ago

    Why This Company is Set for a Major Breakout

    HENDERSON, NV / ACCESSWIRE / October 15, 2018 / With the broader market tanking it is likely investors will find safe haven in cannabis and biotech stocks because they are both innovative sectors. An incredibly ...

  • 5 of the Most Unique Marijuana Stocks
    Motley Fool18 hours ago

    5 of the Most Unique Marijuana Stocks

    These pot stocks stand out in a very crowded field.

  • ACCESSWIRE19 hours ago

    Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Aerie Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...

  • How to Invest in Marijuana Stocks
    Motley Fool4 days ago

    How to Invest in Marijuana Stocks

    Seven straightforward steps to help you invest in high-growth -- but high-risk -- marijuana stocks.

  • Investopedia5 days ago

    How GW Pharmaceuticals is Changing the Cannabis Game in the U.S.

    One of the hottest areas in the investment world today is legal cannabis. Although marijuana and related products are not fully legal across the United States, the move by individual states to legalize cannabis for medical or, in some cases, recreational use has opened up many avenues for potential investment opportunities. GW Pharmaceuticals PLC ADR ( GWPH) is a biopharmaceutical company headquartered in the U.K. GW aims to develop products within the medical cannabis portion of the legal marijuana industry.

  • ACCESSWIRE6 days ago

    Top Beverage Companies Entering CBD

    HENDERSON, NV / ACCESSWIRE / October 10, 2018 / Molson Coors became the latest major beverage company to announce plans to start their own CBD beverage arm. Coca-Cola and InBev have also announced similar ...

  • Marijuana ETFs: How to Find the Best Exchange-Traded Funds
    Motley Fool7 days ago

    Marijuana ETFs: How to Find the Best Exchange-Traded Funds

    If you're interested in profiting from the marijuana movement, you might want to consider owning a marijuana exchange-traded fund.

  • Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
    Motley Fool9 days ago

    Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

    Despite getting lumped in with riskier marijuana stocks, these two biotechs are worth a closer look.

  • Why GW Pharmaceuticals Stock Jumped 17.7% in September
    Motley Fool10 days ago

    Why GW Pharmaceuticals Stock Jumped 17.7% in September

    This marijuana stock had a good month last month thanks to a regulatory first. Here's what investors should know.

  • Benzinga10 days ago

    Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

    In market-related news, shares of Tilray Inc (NASDAQ: TLRY) tumbled Tuesday, after beverage giant PepsiCo, Inc. (NASDAQ: PEP) put an end to speculation about a potential entry into the cannabis space. “I think the difficulties in investing in that category, particularly in the U.S., where federally these things are still not legal, are quite a considerable challenge,” PepsiCo Chief Financial Officer Hugh Johnston said on a company call. GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) said it was issuing 1.9 million ADSs in a bid to raise $300 million.

  • GW Pharmaceuticals: Recommendations and Market Capitalization
    Market Realist10 days ago

    GW Pharmaceuticals: Recommendations and Market Capitalization

    GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.

  • New Age Beverages Stock Bubbles Higher on Upcoming CBD Drinks Launch
    InvestorPlace11 days ago

    New Age Beverages Stock Bubbles Higher on Upcoming CBD Drinks Launch

    According to New Age Beverages (NASDAQ:NBEV) CEO Brent Willis, the company is preparing to show off its new line of CBD drinks next week. While that’s good news for New Age Beverages stock, it isn’t the major launch that some investors may be hoping for. Instead, the company is still talking to retailers about selling the drinks in states where they are legal.

  • GW Pharmaceuticals: Q3 Performance, Q4 Estimates
    Market Realist11 days ago

    GW Pharmaceuticals: Q3 Performance, Q4 Estimates

    GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.

  • Marijuana-Focused Biotech Companies in Q3: Are They Performing?
    Market Realist11 days ago

    Marijuana-Focused Biotech Companies in Q3: Are They Performing?

    Biotechnology companies focused on marijuana-based products include GW Pharmaceuticals (GWPH), Cara Therapeutics (CARA), and Insys Therapeutics (INSY). In this series, we’ll look at these stocks and how they performed in the third quarter.

  • ACCESSWIRE11 days ago

    Cannabis Industry Service Provider Solving Major Challenges

    HENDERSON, NV / ACCESSWIRE / October 5, 2018 / One of the major reasons cannabis stocks are doing so well is because they are potential solutions to long standing challenges, such as the opioid epidemic. ...

  • GlobeNewswire11 days ago

    GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs, Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs

    GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of 1,900,000 American Depositary Shares (“ADSs”) and the full exercise by the underwriters of their option to purchase 285,000 additional ADSs from GW at a price to the public of $158.00 per ADS, raising gross proceeds of $345,230,000 (before deducting underwriting discounts, commissions and offering expenses).

  • Benzinga13 days ago

    The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Boston Scientific Corporation (NYSE: BSX ) Eli Lilly ...

  • GlobeNewswire13 days ago

    GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million

    GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company.

  • Investor's Business Daily14 days ago

    Dow Jones Futures: Hot IPO Stitch Fix Dives, Marijuana Stocks India Global, New Age Beverages Swing Wildly

    Stock futures: Hot IPO Stitch Fix earnings topped, but other metrics missed. Stitch Fix stock dived. Marijuana plays New Age Beverages, India Globalization and DavidsTea were volatile.

  • ACCESSWIRE14 days ago

    DEA Rescheduling Makes CBD Stocks Blazing Hot

    HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The DEA has just made a move that makes that has investors fired up.Last week, U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval. The agency announced Thursday that drugs including "finished dosage formulations" of CBD with THC below 0.1% will be considered Schedule 5 drugs, as long as the medications have been approved by the U.S. Food and Drug Administration. This has made CBD stocks even hotter than they have been.CBD stallwarts like GW Pharma, who was a large reason for this ruling are obviously benefitting, however, for investors looking to maximize their profit potential from this ruling it's beneficial to dig a little deeper.

  • Benzinga14 days ago

    The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...

  • MarketWatch14 days ago

    Medical-marijuana company GW Pharma to sell $300 million in stock offering

    GW Pharmaceuticals PLC said late Monday that it plans to sell $300 million worth of American depositary shares. Shares in the company fell 1.6% after hours. GW is a U.K.-based pharmaceutical company that seeks to make products with cannabis. The underwriters have an option to buy $45 million more shares within 30 days. Goldman Sachs, Morgan Stanley, J.P. Morgan and Cowen and Company are acting as joint book-running managers for the offering. GW stock closed down 3.3% to $167.10 in Monday trading. GW stock has gained 27% this year as the S&P 500 index rose 9.4%.

  • GlobeNewswire14 days ago

    GW Pharmaceuticals Announces Proposed Public Offering of ADSs

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform and whose U.S. subsidiary is Greenwich Biosciences, announced today that it intends to sell, subject to market and other conditions, $300 million of American Depositary Shares (“ADSs”) representing ordinary shares of GW on the Nasdaq Global Market in an underwritten U.S. public offering.  GW expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of ADSs at the offering price. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • InvestorPlace15 days ago

    2 Marijuana Biotechs to Watch

    On Sept. 27, the United States Drug Enforcement Agency (DEA) made official a long-awaited decision on a cannabidiol (CBD)-based drug. GW Pharmaceuticals’ (NASDAQ:GWPH) drug Epidiolex was reclassified from Schedule 1 to Schedule 5.